Zacks Investment Research
05 Aug 2026, 23:11 UTC · 2h ago
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
05 Aug 2026, 23:11 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Editas Medicine reported quarterly revenue of $11.89 million, exceeding the Zacks Consensus Estimate by 524.80%. — A massive revenue beat typically signals strong commercial growth or successful milestone payments, driving positive sentiment.
+0.60Editas reported a quarterly loss of $0.15 per share, which was significantly better than the estimated loss of $0.30 per share. — Outperforming earnings expectations by 50% indicates better-than-expected cost management or operational efficiency.
+0.40The company's quarterly revenue of $11.89 million represents a substantial increase from the $3.58 million reported a year ago. — Strong year-over-year growth demonstrates an accelerating business trajectory for the company.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company reported a significant earnings surprise and revenues that surpassed estimates by over 500%.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1h ago
